Physician profile
Susan E Bates
NPI 1508080029
$3,647.51
in general payments reported to CMS, 2019-2025
9 companies · $19.86 in 2025
The $19.86 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,756 · 2023: $43.22 · 2024: $829 · 2025: $19.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $728 · Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $727.50 |
| Food and Beverage | $164.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $2,777.40 | 2022-2023 | Onivyde, Somatuline Depot |
| Daiichi Sankyo INC. | $828.73 | 2024 | |
| Incyte Corporation | $21.52 | 2023 | Pemazyre |
| Beigene USA, INC. | $19.86 | 2025 | Tevimbra |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.